|
市場調查報告書
Warner-Chilcott Plc:企業分析
Warner-Chilcott Plc: PharmaVitae Report
| 出版商 |
Datamonitor |
| 出版日期 |
2011年11月 |
商品編碼 |
229458 |
| 內容資訊 |
英文 Pages: 62 |
| 價格 |
|
|
Warner-Chilcott Plc:企業分析 是由出版商Datamonitor在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 62 價格從美金5700起跳。
本報告提供在醫藥品產業的Warner-Chilcott Plc，其現在·未來的業績趨勢相關分析，主要產品的開發·銷售趨勢，財務業績的實際成果值及預測值(都是6年份)，企業簡介，產業策略的資訊，為您概述為以下內容。
執行摘要
- 主要的分析結果
- 處方藥的銷售額預測
- 財務狀況預測
- 主要的發展
- SWOT分析
關於本報告
- PharmaVitae:企業資料資料庫
- 本報告的章節組成
- 資料的資訊來源
策略性考察
- 透過收購了Proctor & Gamble的醫藥品部門，達到了到2016年業績的改善效果
- 產品結構的大幅變化
- 由於主力產品的減少，專利到期影響增大
- 關於專利失效的交涉為不可能:事前現金流量的準備，為今後發展不可或缺
- 透過收購P&G醫藥品部門，預測業績將大幅提升
- 為了產品更進一步多樣化、及策略性進化，平台的結構
企業概要
銷售額分析
- 主要的分析結果
- 處方藥的銷售額與其增加率分析(2004∼2016年)
- 產品分析
- 治療領域分析
- 地區分析
- 新銷售/主力品/專利結束分析
- 說明
- 新銷售分析(2010∼2016年)
- 主力品分析(2010∼2016年)
- 專利結束分析(2010∼2016年)
- 新銷售/主力品/專利結束的形態(2010∼2016年)
- 分子類型分析
- 外部分析
財務分析
- 主要的分析結果
- PharmaVitae資料庫的處方藥銷售額資料與企業發表資料間差異的調整(2004∼2010年)
- 營業成本效益分析
- 營業成本效益分析(2004∼2010年)
- 營業成本比率·報酬率分析(2004∼2010年)
- 營業成本比率·報酬率分析(2010∼2016年)
- 營業成本效益分析(2010∼2016年)
產品分析
- 概要
- Asacol
- Actonel
- Enablex
- Loestrin
- Estrace
- Doryx
附錄
Description
Introduction
This analysis examines the historical and forecast performance for Warner-Chilcott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Warner-Chilcott's strategic outlook across the next 6 years.
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights
- Strategic insight into the prospects for Warner Chilcott over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Warner-Chilcott's performance against key rivals in the prescription pharmaceutical sector
- Assess how Warner-Chilcott has transformed its prescription pharmaceutical business via the acquisition of Proctor & Gamble's pharma unit
- Analyze how increased scale will not translate to robust sales growth over 2010-16, due to the exposure of key acquired brands to generic competition
TOC
Executive Summary
- Key findings
- Warner Chilcott prescription pharma sales outlook
- Warner Chilcott financial outlook
- SWOT analysis
- Weaknesses
- Opportunities
- Threats
ABOUT THIS REPORT
- PharmaVitae Explorer database
- Chapter structure
- Strategic insight
- Company introduction
- Sales analysis
- Financial analysis
- Product analysis
- Data sourcing
STRATEGIC INSIGHT
- Proctor & Gamble acquisition will shape performance through to 2016
- Portfolio has undergone substantial change
- Impact of expiries increased by narrower product focus
- Patent expiries non-negotiable - pre-erosion cash flow critical to future expansion
- P&G acquisition will drive superior operating performance…
- …and provide platform for further diversification and strategic evolution
COMPANY INTRODUCTION
SALES ANALYSIS
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2004-16
- Product analysis
- Product analysis, 2010-16
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2010-16
- Core analysis, 2010-16
- Expiry analysis, 2010-16
- Launch/core/expiry configuration, 2010-16
- Molecule type analysis
- Externalization analysis
FINANCIAL ANALYSIS
- Key findings
- Operating costs and profit analysis
- Operating costs and profit analysis, 2004-10
- Operating cost ratio and profit margin analysis, 2004-10
- Operating cost ratio and profit margin analysis, 2010-16
- Operating costs and profit analysis, 2010-16
PRODUCT ANALYSIS
- Overview
- Asacol
- Actonel
- Enablex
- Loestrin
- Estrace
- Doryx
APPENDIX
- References
- Exchange rates
|
